Skip Navigation

Neuro-Oncology 2006 8(1):27-37; doi:10.1215/S1522851705000323
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hoffman, S.
Right arrow Articles by McCarthy, B. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hoffman, S.
Right arrow Articles by McCarthy, B. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 by the Society for Neuro-Oncology

Temporal trends in incidence of primary brain tumors in the United States, 1985-19991

Sara Hoffman, Jennifer M. Propp and Bridget J. McCarthy2

Department of Epidemiology, University of Illinois at Chicago, Chicago, IL 60612, USA

2 Address correspondence to Bridget J. McCarthy, Department of Epidemiology, University of Illinois at Chicago, 1603 W. Taylor, M/C 923, Chicago, IL 60612 (bjm3{at}uic.edu).


   Abstract

A number of reports have indicated an increasing incidence of primary brain tumors over the past few decades. The purpose of this study was to describe incidence rate trends in a population-based series of newly diagnosed primary nonmalignant and malignant brain and other CNS tumors, contributing five additional years to previously published incidence trends. Data for the years 1985 through 1999 from six collaborating state cancer registries of the Central Brain Tumor Registry of the United States were used to determine incidence trends in the broad age groups 0-19, 20-64, and ≥65 years, overall and for selected histologies. Multiplicative Poisson regression was used to express trends as average annual percent change (AAPC). Joinpoint regression was used to identify sharp changes in incidence occurring over this period. Overall, incidence increased modestly (AAPC, 1.1; 95% CI, 0.8-1.4). When brain lymphomas were excluded, this increase remained statistically significant. A sharp change in incidence of brain lymphomas from increasing to decreasing over time was identified. Specific histologies that were increasing included anaplastic astrocytomas in individuals aged ≥65 years, microscopically confirmed gliomas in both adult age groups, and microscopically confirmed glioma, not otherwise specified (NOS), in children. Increases that were not specific to any population subgroup were seen for oligodendrogliomas, ependymomas, meningiomas, and nerve sheath tumors. Decreases were noted for astrocytoma, NOS, nonmicroscopically confirmed gliomas, and pituitary tumors. Improvements in diagnosis and classification are likely reflected in the decreasing trends in unspecified glioma subgroups and the accompanying increasing trends in more specific glioma subgroups. However, increases in meningiomas and nerve sheath tumors deserve further attention.

Keywords: brain tumors, epidemiology, incidence, trends

Received March 17, 2005; Accepted July 21, 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Neuro OncologyHome page
R. S. Arora, R. D. Alston, T. O.B. Eden, E. J. Estlin, A. Moran, and J. M. Birch
Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England
Neuro Oncology, August 1, 2009; 11(4): 403 - 413.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. J. Lau, Z. Koty, and J. Nalbantoglu
Differential Response of Glioma Cells to FOXO1-Directed Therapy
Cancer Res., July 1, 2009; 69(13): 5433 - 5440.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncologyHome page
S. Phuphanich, K. A. Carson, S. A. Grossman, G. Lesser, J. Olson, T. Mikkelsen, S. Desideri, J. D. Fisher, and for the New Approaches to Brain Tumor Therapy (NAB
Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma
Neuro Oncology, August 1, 2008; 10(4): 617 - 623.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.